Researchers from Louisiana State University (LSU) are collaborating with the University of Chicago and 13 other research institutions to evaluate an immunosuppressant drug's potential to prevent the recurrence of head and neck cancer.
Cherie-Ann Nathan of LSU Health Shreveport and colleagues have been awarded a $1.24 million National Cancer Institute (NCI) grant to study rapamycin, an antirejection drug used in organ transplant patients.
Initial studies found that rapamycin blocks a cellular pathway that can signal cells to become cancerous.
As part of this new study, LSU Health Shreveport will test patient samples from all the sites. The study will take four or five years and involve up to 160 people.
